Notes to editor
This press release accompanies both a presentation and an ESC press conference at ESC Congress 2025.
It does not necessarily reflect the opinion of the European Society of Cardiology.
ESC Press Office
Tel: +33 6 61 40 18 84
Email: press@escardio.org
Follow European Society of Cardiology News on LinkedIn*
Funding: The trial was supported by research grants from the Ministry of Health & Welfare, Republic of Korea and Samjin Pharmaceutical Co. Ltd.
Disclosures: Professor Joung has nothing to disclose directly related to this presentation. He has served as a speaker for Bayer, BMS/Pfizer, Medtronic and Daiichi-Sankyo and received research funds from Samjin, Yuhan, Medtronic, Boston Scientifics and Abbott Korea. No fees were received personally.
References and notes:
1‘ALONE-AF: Discontinuing long-term oral anticoagulation after successful atrial fibrillation ablation’ presented during HOT LINE 8 on 31 August 2025 at 17:30 to 17:40 in Madrid (Main Auditorium) and simultaneously published in The Journal of the American Medical Association.
2Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45:3314−3414.
About ESC Congress 2025
It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Madrid and online – from 29 August to 1 September 2025. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.
About the European Society of Cardiology
The ESC brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.